Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

101.43 -1.10 (-1.07%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

70 71 Next >

What 12 Analyst Ratings Have To Say About BioNTech ↗

April 10, 2023

Via Benzinga

Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal ↗

April 08, 2023

Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...

Via Talk Markets

Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗

April 04, 2023

Via Benzinga

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech

April 04, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

A Look Into BioNTech Inc's Price Over Earnings ↗

April 03, 2023

Via Benzinga

Bear of the Day: BioNTech ↗

March 28, 2023

BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines.

Via Talk Markets

These Analysts Revise Price Targets On BioNTech After Q4 Results ↗

March 28, 2023

BioNTech SE (NASDAQ: BNTX) reported a decline in sales for its fourth quarter.

Via Benzinga

Why Shares of BioNTech Slumped Monday ↗

March 27, 2023

The company released fourth-quarter earnings.

Via The Motley Fool

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

April 03, 2023

From BioNTech SE

Via GlobeNewswire

Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review ↗

March 31, 2023

The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica.

Via Investor's Business Daily

NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 28, 2023

B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8%...

Via Benzinga

BioNTech Earnings Preview ↗

March 24, 2023

Via Benzinga

4 Analysts Have This to Say About BioNTech ↗

March 23, 2023

Via Benzinga

BioNTech Announces New ADS Repurchase Program

March 28, 2023

From BioNTech SE

Via GlobeNewswire

Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories ↗

March 27, 2023

Benzinga

Via Benzinga

BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗

March 27, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

BioNTech Is Ripe For A Rebound In 2023

March 27, 2023

BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.

Via MarketBeat

Topics Intellectual Property

BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion ↗

March 27, 2023

For the year, BioNTech said it expects about $5.4 billion in sales of its Covid shot.

Via Investor's Business Daily

Why BioNTech Shares Are Trading Lower Today ↗

March 27, 2023

BioNTech SE (NASDAQ: BNTX) shares are falling in the premarket session today after the company reported Q4 earnings and expected lower annual revenue from the Covid-19 vaccine.

Via Benzinga

Earnings Scheduled For March 27, 2023 ↗

March 27, 2023

Companies Reporting Before The Bell • Viomi Technology Co (NASDAQ:VIOT) is likely to report earnings for its fourth quarter. • Vislink Technologies (NASDAQ:VISL) is projected to report earnings for its...

Via Benzinga

US Stocks Poised To Start New Trading Week Higher On Hopes Of Resolving Banking Crisis: Analyst Warns 'No News Would Be Good News' ↗

March 27, 2023

The recent positive momentum seen in the market could carry over into the new week, as indicated by the index futures, which were holding up early Monday.

Via Benzinga

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

March 27, 2023

From BioNTech SE

Via GlobeNewswire

Could CRISPR Therapeutics Become the Next Moderna? ↗

March 27, 2023

Both companies use cutting-edge technology.

Via The Motley Fool

Carnival, BioNTech And 3 Stocks To Watch Heading Into Monday ↗

March 27, 2023

With US futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Investor Fear Increases Amid Recent Bank Concerns ↗

March 27, 2023

The CNN Money Fear and Greed index showed some increase in the fear level among U.S. investors. US stocks closed higher on Friday following a volatile trading session. All the major indices recorded...

Via Benzinga

7 Blue-Chip Stocks Sitting in the Sweet Spot ↗

March 23, 2023

Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move.

Via InvestorPlace

China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine ↗

March 22, 2023

Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization.

Via Benzinga

Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks ↗

March 21, 2023

The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk.

Via Benzinga

Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders ↗

March 21, 2023

Moderna CEO Stephane Bancel will face a Senate Committee over pricing plans.

Via Investor's Business Daily

Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information ↗

March 21, 2023

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.